Grifols, S.A. (FRA:G0FB)

Market Cap	5.38B -9.5%
Revenue (ttm)	7.52B +4.3%
Net Income	402.00M +156.1%
EPS	0.59 +156.5%
Shares Out	n/a
PE Ratio	13.38
Forward PE	8.62
Dividend	0.12 (1.92%)
Ex-Dividend Date	Aug 12, 2025

Volume	24
Average Volume	28
Open	6.40
Previous Close	6.45
Day's Range	6.40 - 6.65
52-Week Range	5.75 - 9.55
Beta	n/a
RSI	44.02
Earnings Date	May 5, 2026

About Grifols

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as wel...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1909
• Employees: 25,258
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: G0FB

Financial Performance

In 2025, Grifols's revenue was 7.52 billion, an increase of 4.33% compared to the previous year's 7.21 billion. Earnings were 402.00 million, an increase of 156.05%.